Veritas In Silico Inc. (JP:130A) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Veritas In Silico Inc. has revised its financial forecast for FY2024, anticipating a significant drop in revenue and profits due to delays in securing two new contract agreements. Despite the postponement, the company remains optimistic about future growth, with plans to pursue additional contracts and expand its joint drug discovery research. These efforts aim to enhance long-term business revenue and establish Veritas as a key player in mRNA-related drug discovery.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.